Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H26N2O4S |
Molecular Weight | 414.518 |
Optical Activity | ( + ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)[C@@H]2SC3=CC=CC=C3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O
InChI
InChIKey=HSUGRBWQSSZJOP-RTWAWAEBSA-N
InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
Molecular Formula | C22H26N2O4S |
Molecular Weight | 414.518 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Diltiazem is a nondihydropyridines calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 |
21.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARDIZEM Approved UseDiltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension; thus hypertensive individuals experience an antihypertensive effect, whereas there is only a modest fall in blood pressure in normotensives. Launch Date4.05302411E11 |
|||
Primary | CARDIZEM Approved UseDiltiazem has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal work loads. Diltiazem has been shown to be a potent dilator of coronary arteries, both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasm are inhibited by diltiazem. Launch Date4.05302411E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
166.4 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11329099 |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DILTIAZEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2410 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11329099 |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DILTIAZEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.5 h |
360 mg single, oral dose: 360 mg route of administration: Oral experiment type: SINGLE co-administered: |
DILTIAZEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25% |
360 mg single, oral dose: 360 mg route of administration: Oral experiment type: SINGLE co-administered: |
DILTIAZEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
weak | ||||
yes [IC50 0.6 uM] | ||||
yes [IC50 11 uM] | ||||
yes [IC50 120 uM] | yes (co-administration study) Comment: Diltiazem is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some statins. |
|||
yes [Ki 117 uM] | ||||
yes [Ki 12.5 uM] | ||||
yes [Ki 77.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
no | no (pharmacogenomic study) Comment: results suggest that CYP3A5*3 has only a minor effect on the pharmacokinetics and metabolism of diltiazem Sources: https://pubmed.ncbi.nlm.nih.gov/16024008/ |
|||
yes | ||||
yes | ||||
yes | weak (pharmacogenomic study) Comment: Two of the most frequent alleles, CYP3A5 3 and CYP2D6 10, among Chinese do not have major impacts on the disposition of diltiazem and N-desmethyl diltiazem. However, the desacetyl diltiazem showed 2-fold accumulation in individuals with CYP2D6 10/10 genotype |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Physiology in medicine: importance of hypoxic pulmonary vasoconstriction in maintaining arterial oxygenation during acute respiratory failure. | 2001 |
|
Calcium channel blockers for neuroleptic-induced tardive dyskinesia. | 2001 |
|
[Dilren efficacy in postmyocardial infarction patients]. | 2001 |
|
[Unexpected formation of spiro(benzofuran-2,2'-(1,4)benzothiazines) from aurones]. | 2001 Apr |
|
Slowing the progression of renal disease in diabetic patients. | 2001 Apr |
|
Topical diltiazem ointment in the treatment of chronic anal fissure. | 2001 Apr |
|
Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. | 2001 Apr |
|
Involvement of calcium signaling in the fibronectin-stimulated macrophage recognition of oxidatively damaged erythrocytes. | 2001 Apr 23 |
|
Atrial fibrillation control and cardioversion. | 2001 Apr 7 |
|
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case. | 2001 Feb |
|
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. | 2001 Feb |
|
Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. | 2001 Feb |
|
Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal rat cardiomyocytes. | 2001 Feb |
|
L-type calcium channel blockers and EGTA enhance superoxide production in cardiac fibroblasts. | 2001 Feb |
|
Diltiazem comes in from the cold. | 2001 Feb |
|
Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells. | 2001 Feb |
|
Axonal L-type Ca2+ channels and anoxic injury in rat CNS white matter. | 2001 Feb |
|
Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. | 2001 Feb 1 |
|
Diltiazem downregulates IL-12 production by human dendritic cells. | 2001 Feb-Mar |
|
Diltiazem affects human dendritic cell maturation. | 2001 Feb-Mar |
|
Muscarinic activation of transient inward current and contraction in canine colon circular smooth muscle cells. | 2001 Jan |
|
Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem. | 2001 Jan |
|
Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use. | 2001 Jan |
|
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols. | 2001 Jan |
|
Potential role of eNOS in the therapeutic control of myocardial oxygen consumption by ACE inhibitors and amlodipine. | 2001 Jan |
|
An in vitro investigation of the suitability of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobic additives in the outer shell for colon targeting. | 2001 Jan 29 |
|
Design and evaluation of microcapsules of diltiazem hydrochloride. | 2001 Jan-Feb |
|
[Parkinson syndrome from diltiazem]. | 2001 Jan-Feb |
|
Na+ effects on mitochondrial respiration and oxidative phosphorylation in diabetic hearts. | 2001 Jun |
|
Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. | 2001 Jun |
|
Photostability and phototoxicity studies on diltiazem. | 2001 Jun |
|
Analysis of multicomponent formulations containing phenylpropanolamine hydrochloride, caffeine and diazepam by using LC. | 2001 Jun |
|
Adsorptive stripping voltammetric determination of antihypertensive agent: diltiazem. | 2001 Jun |
|
cAMP modulates the excitability of immortalized H=hypothalamic (GT1) neurons via a cyclic nucleotide gated channel. | 2001 Jun |
|
Smooth muscle relaxation and local hydraulic impedance properties of the aorta. | 2001 Jun |
|
Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. | 2001 Jun |
|
Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. | 2001 Jun |
|
An alternative method to the evaluation of similarity factor in dissolution testing. | 2001 Jun 4 |
|
Clinical outcomes of aneurysmal subarachnoid hemorrhage patients treated with oral diltiazem and limited intensive care management. | 2001 Mar |
|
Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca(2+) homeostasis. | 2001 Mar |
|
Positive and negative contractile effects of somatostatin-14 on rat ventricular cardiomyocytes. | 2001 Mar |
|
Effect of magnesium stearate or calcium stearate as additives on dissolution profiles of diltiazem hydrochloride from press-coated tablets with hydroxypropylmethylcellulose acetate succinate in the outer shell. | 2001 Mar 23 |
|
Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. | 2001 Mar 9 |
|
Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. | 2001 May |
|
Dilitiazem reduces nitric oxide production by human immune cells. | 2001 May |
|
Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). | 2001 May |
|
Diltiazem treatment does not alter renal function after thoracic surgery. | 2001 May |
|
Calcium-channel antagonists and nitrates in coronary artery bypass patients receiving radial artery grafts. | 2001 May |
|
Trimetazidine for stable angina pectoris. | 2001 May |
|
Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. | 2001 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/dilt-cd.html
When used as monotherapy, reasonable starting doses are 180 to 240 mg once daily, although some patients may respond to lower doses. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, dosage adjustments should be scheduled accordingly. The usual dosage range studied in clinical trials was 240 to 360 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. Dosages for the treatment of angina should be adjusted to each patient's needs, starting with a dose of 120 or 180 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. When necessary, titration may be carried out over a 7- to 14-day period.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7473567
Tissue homogenate of cerebral cortext and heart containing calcium channel receptors was used in a radioligand-binding assays. Cerebral cortices of male SD rats were homogenized. Hearts were also removed, perfused through aorta with ice-cold saline solution, and homogenized. Subsequently, the cardiac homogenates were filtered through four layers of cloth. Both cortical and cardiac homogenates were washed 5 times by centrifugation for 10 min at 48000 g. The final pelle was resuspended to a conc. of 50 mg of original wet tissue wt/mL of buffer and stored at -70°C. Tissue homogenate (200 uL) was incubated for 90 min in a dark room at 0°C with 100 uL of [3H]nitreddipine (3x10^-10M, 87 Ci/mmol) and 100 uL of the test compound dissolved in DMSO in 50 mM of Na-Hepes buffer, pH 7.4. The incubations were stopped by adding 4 mL of cold buffer followed by rapid filtratoin through glass fiber filter disks. The samples were subsequently washed 3 times with 4.5 mL of the same buffer and placed into scintill. vials. Diltiazem inhibited binding of [3H]nitrendipine with Ki of 21 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 18:37:34 UTC 2022
by
admin
on
Sun Dec 18 18:37:34 UTC 2022
|
Record UNII |
EE92BBP03H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08DB01
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
||
|
WHO-ATC |
C08DB01
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
||
|
NDF-RT |
N0000000069
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
||
|
LIVERTOX |
NBK547898
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
||
|
WHO-ATC |
C05AE03
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
||
|
NDF-RT |
N0000175566
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EE92BBP03H
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
42399-41-7
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
2298
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
39186
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
255-796-4
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
EE92BBP03H
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
CHEMBL23
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
DB00343
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
6528
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
3433
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
M4494
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | Merck Index | ||
|
SUB07148MIG
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
Diltiazem
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
DTXSID9022940
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
D004110
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
897
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
101278
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
3443
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | RxNorm | ||
|
DILTIAZEM
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY | |||
|
C61725
Created by
admin on Sun Dec 18 18:37:36 UTC 2022 , Edited by admin on Sun Dec 18 18:37:36 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
In some plasma samples
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|